The critical role of leukotriene B4 in antigen‐induced mechanical hyperalgesia in immunised rats
- 1 July 2003
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (6) , 1135-1145
Abstract
We investigated the mediators responsible for mechanical hypersensitivity induced by antigen challenge in rats immunised with ovalbumin (OVA). Challenge with OVA (12.5–100 μg, intraplantar) caused a dose‐ and time‐dependent mechanical hypersensitivity, which peaked 3 h after, decreased thereafter and reached control levels 24 h later. Levels of TNFα, IL‐1β and cytokine‐induced neutrophil chemoattractant 1 (CINC‐1) were increased in paw skin after antigen challenge. OVA‐evoked hypersensitivity was partially inhibited (about 51%) by pretreatment with anti‐TNFα, IL‐1β and IL‐8 sera or with IL‐1 receptor antagonist (IL‐1ra), but not anti‐NGF serum. Pretreatment with thalidomide (45 mg kg−1) or pentoxifylline (100 mg kg−1) also partially inhibited the hypersensitivity at 1–3 h after challenge. Pretreatment with indomethacin (5 mg kg−1) or atenolol (1 mg kg−1) reduced the OVA‐induced hypersensitivity at 1 and 3 h, but not at 5 h after challenge, while the combination of B1 and B2 bradykinin receptor antagonists was ineffective over the same times. Pretreatment with MK886 (5‐lipoxygenase‐activating protein inhibitor, 3 mg kg−1), CP 105696 (LTB4 receptor antagonist; 3 mg kg−1) or dexamethasone (0.5 mg kg−1) inhibited the hypersensitivity from 1 to 5 h. Furthermore, LTB4 levels were increased in the paw skin of challenged rats. In conclusion, our results suggest that the TNFα‐, IL‐1β‐ and CINC‐1‐driven release of prostaglandins, sympathetic amines and LTB4 mediates the first 3 h of mechanical hypersensitivity induced by antigen challenge in rats. At 5 h after OVA administration, although TNFα has some role, LTB4 is the critical nociceptive mediator. British Journal of Pharmacology (2003) 139, 1135–1145. doi:10.1038/sj.bjp.0705346Keywords
This publication has 76 references indexed in Scilit:
- Bradykinin B1 and B2 receptors, tumour necrosis factor α and inflammatory hyperalgesiaBritish Journal of Pharmacology, 1999
- (+)-1-(3S,4R)-[3-(4-Phenylbenzyl)-4- hydroxychroman-7-yl]cyclopentane Carboxylic Acid, a Highly Potent, Selective Leukotriene B4 Antagonist with Oral Activity in the Murine Collagen-Induced Arthritis ModelJournal of Medicinal Chemistry, 1994
- Bradykinin release of TNF-α plays a key role in the development of inflammatory hyperalgesiaInflammation Research, 1993
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993
- Biologically active products of stimulated liver macrophages (Kupffer cells)European Journal of Biochemistry, 1990
- Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofyllineBiochemical and Biophysical Research Communications, 1988
- Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes.Journal of Clinical Investigation, 1987
- A peripheral sympathetic component in inflammatory hyperalgesiaEuropean Journal of Pharmacology, 1987
- Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processesInflammation Research, 1981
- Effects of regional guanethidine infusion in certain painful states.Journal of Neurology, Neurosurgery & Psychiatry, 1980